Mesenchymal Stromal Cells for COVID-19 and Viral Pneumonias

Summary

This is an open-label phase 1 clinical trial of allogeneic umbilical cord derived mesenchymal stromal cells (MSCs) for hospitalized individuals with COVID-19 or other viral pneumonias. Hospitalized individuals who are within 7 days of the onset of a viral pneumonia will be given 2 doses of MSCs at days 1 and 3 after consent. The safety of intravenous infusion will be tested and course of the oxygen response to treatment over 90 days will be evaluated.

Timeline

Start

2024-10-01

Primary completion

2024-10-01

Completion

2024-10-01

Outcome

Outcome not reported

Stopped (Business): “Funding”

Drugs

Indications